KPV

⏱ Half-Life

Short duration profile

KPV demonstrates a short half-life characteristic in research literature, shaping how observation windows and study timelines are typically structured.

⚡ Onset Characteristics

Moderate measurable response

Onset is observed as moderate — a property that influences how researchers structure comparative studies versus other compounds in the signalling research category.

🧠 Key Notes

What makes it distinct

• 01Derived from the C-terminus of α-MSH (residues 11–13)
• 02Studied across oral, topical, and injectable research routes
• 03Retains anti-inflammatory activity without melanocortin receptor pigmentation effects

🧬 Mechanism of Action

How it works

KPV (Lysine-Proline-Valine) is the C-terminal tripeptide fragment of α-MSH. It enters cells and translocates to the nucleus, where it interferes with NF-κB signalling — a master regulator of pro-inflammatory cytokine expression. By dampening NF-κB activation, KPV downregulates TNF-α, IL-1β, IL-6, and other inflammatory mediators. Unlike full-length α-MSH, KPV does not appreciably activate melanocortin receptors, so it retains anti-inflammatory activity without driving pigmentation pathways. Research also describes inhibition of mast-cell degranulation and modulation of inducible nitric oxide synthase (iNOS).

✨ Documented Benefits

What the research shows it supports

🔍 Research Insights

What the literature shows

🧪 Typical Research Use Cases

Where it appears in study design